2019
Pruritic reticulation: don't ‘fiddle’ around
Salam A, Peleva E, Cowper SE, Leventhal JS. Pruritic reticulation: don't ‘fiddle’ around. Clinical And Experimental Dermatology 2019, 45: 501-504. PMID: 31762054, DOI: 10.1111/ced.14135.Peer-Reviewed Case Reports and Technical NotesThe rash in life-threatening metabolic and endocrine disorders
Mirza FN, Leventhal JS. The rash in life-threatening metabolic and endocrine disorders. Clinics In Dermatology 2019, 38: 79-85. PMID: 32197751, DOI: 10.1016/j.clindermatol.2019.10.018.Peer-Reviewed Original ResearchConceptsEndocrine disordersCutaneous manifestationsLethal complicationSkin manifestationsSystemic disordersEarly diagnosisNutritional diseasesDisordersInternal healthRashManifestationsMorbidityComplicationsAdrenalsParathyroidNeuroendocrineThyroidMortalityPancreasCliniciansDermatologistsDiseaseDiagnosisBlood
2018
Inflammatory eruptions associated with immune checkpoint inhibitor therapy: A single-institution retrospective analysis with stratification of reactions by toxicity and implications for management
Coleman E, Ko C, Dai F, Tomayko MM, Kluger H, Leventhal JS. Inflammatory eruptions associated with immune checkpoint inhibitor therapy: A single-institution retrospective analysis with stratification of reactions by toxicity and implications for management. Journal Of The American Academy Of Dermatology 2018, 80: 990-997. PMID: 30399387, PMCID: PMC6420863, DOI: 10.1016/j.jaad.2018.10.062.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalAntineoplastic Combined Chemotherapy ProtocolsDrug EruptionsExanthemaFemaleHumansIpilimumabLichenoid EruptionsMaleMiddle AgedNivolumabRetrospective StudiesSkin NeoplasmsStevens-Johnson SyndromeWithholding TreatmentConceptsInflammatory eruptionsCheckpoint inhibitorsTherapeutic responseImmune checkpoint inhibitor therapySingle tertiary care centerSingle-institution retrospective analysisYale-New Haven HospitalCheckpoint inhibitor therapyTertiary care centerMinority of patientsInpatient dermatology serviceDegree of severityMost rashesInhibitor therapyRetrospective studyTopical treatmentEarly recognitionMedical recordsCare centerInflammatory reactionRetrospective analysisDermatology servicesImmunotherapyMean latencyGrade 2